Real World Perspectives: Considerations and Challenges for CAR T-cell Therapy in Relapsed/Refractory DLBCL

Video content above is prompted by the following:

Please give an overview of outstanding challenges for both patients and practitioners with the CAR T-cell regimen.

• How can T-cell exhaustion be combated?
• What are the advantages and limitations of outpatient administration. In your opinion, how can any issues with outpatient administration be addressed?
• What other logistical barriers are present with CAR T-cell regimens, and how does bridging therapy help address these concerns?
• What are your thoughts on the use of polatuzumab (pola) in bridging therapy (Liebers et al. Blood Adv 2021; Kim et al. ASH 2024)?

For a patient who does not receive 2L cellular therapy whether based on logistical or clinical reasons, what are the available treatment options?

• Please discuss key takeaways from pola+ BR (Sehn et al. Blood Adv. 2022). What can we learn from these updates?
• What are the major findings from L-MIND, and how does that compare to real world data (Duell J et al. Haematologica 2021; Zinzani et al. Clin Cancer Res 2021)?
• In your practice, how would you choose between the available options?